TACE with or without systemic therapy?

Journal of Hepatology

Volumn 56, Issue 6, 2012, Pages 1224-1225

  Dufour, Jean François ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVANIB; EVEROLIMUS; PLACEBO; SORAFENIB; VASCULOTROPIN;

CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; DRUG EFFICACY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; LIVER CELL CARCINOMA; MONOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMIC THERAPY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; PYRIDINES;

EID: 84861195525     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.02.011     Document Type: Editorial

References (16)

1. J.M. Llovet, M.I. Real, X. Montana, R. Planas, S. Coll, and J. Aponte Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739 (Pubitemid 34607087)
2. C.M. Lo, H. Ngan, W.K. Tso, C.L. Liu, C.M. Lam, and R.T. Poon Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171 (Pubitemid 34454013)
3. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442 (Pubitemid 36152543)
4. C. Camma, F. Schepis, A. Orlando, M. Albanese, L. Shahied, and F. Trevisani Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials Radiology 224 2002 47 54 (Pubitemid 34680374)
5. J. Lammer, K. Malagari, T. Vogl, F. Pilleul, A. Denys, and A. Watkinson Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
6. J.F. Dufour, and P. Johnson Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference J Hepatol 52 2010 296 304
7. X. Li, G.S. Feng, C.S. Zheng, C.K. Zhuo, and X. Liu Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level World J Gastroenterol 10 2004 2878 2882 (Pubitemid 39303010)
8. A. Sergio, C. Cristofori, R. Cardin, G. Pivetta, R. Ragazzi, and A. Baldan Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness Am J Gastroenterol 103 2008 914 921 (Pubitemid 351506379)
9. J.F. Dufour, H. Hoppe, M.H. Heim, B. Helbling, O. Maurhofer, and Z. Szucs-Farkas Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study Oncologist 15 2010 1198 1204
10. J.W. Park, Y. Koh, H. Kim, H. Kim, S. An, and J.-I. Choi Phase II study of concurrent transarterial chemoembolization and sorafenib for patients with unresectable hepatocellular carcinoma J Hepatol 56 2012 1336 1342
11. J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
12. B.M. Strebel, and J.F. Dufour Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease Expert Rev Anticancer Ther 8 2008 1743 1749
13. A. Erhardt, F. Kolligs, M. Dollinger, E. Schott, H. Wege, and M. Bitzer TACE plus sorafenib for the treatment of hepatocellular carcinoma: final results of the multicenter SOCRATES trial J Clin Oncol 29 2011
14. T.M. Pawlik, D.K. Reyes, D. Cosgrove, I.R. Kamel, N. Bhagat, and J.F. Geschwind Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma J Clin Oncol 29 2011 3960 3967
15. Lencioni R, Llovet J, Han G, Tak W, Yang J, Leberre M, et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012;Suppl. LBA154.
16. A.C. Piguet, B. Saar, R. Hlushchuk, M.V. St-Pierre, P.M. McSheehy, and V. Radojevic Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma Mol Cancer Ther 10 2011 1007 1017